The newly approved patents have increased IceCure's patent portfolio to 42 in the United States, Europe, and Asia, further strengthening its intellectual property protection in key international markets.
Caesarea, Israel, November 9, 2026 / PRNewswire / -- IceCure Medical Ltd. (Nasdaq ticker: ICCM) ("IceCure", "IceCure Medical" or "the Company") announced today that the China National Intellectual Property Administration ( CNIPA ) has granted the Company a new patent covering a connector used in its cryogenic technology platform, thereby further expanding the Company's global intellectual property portfolio and strengthening its protection of proprietary cryogenic technologies in key international markets.
This patented connector belongs to the low-temperature technology platform of IceCure, and the approval of this patent comes shortly after the company recently achieved a regulatory milestone in China. In September 2026, IceCure was approved by the National Medical Products Administration of China, allowing the sale of ProSense ® and its accompanying cryoprobe in China.
The intellectual property portfolio of IceCure includes a total of 42 patents in the United States, Europe, the United Kingdom, China, and Japan.
IceCure indicates that its intellectual property portfolio covers its technical platforms and proprietary technologies, including innovations to be incorporated into current and future products. The company continues to protect and expand its intellectual property portfolio in the international market to support its long-term technical strategy and safeguard its proprietary innovations.
About IceCure Medical
IceCure Medical (Nasdaq ticker: ICCM) develops and sells advanced cryoablation therapy systems based on liquid nitrogen, which destroy tumors (both benign and malignant) through freezing. This approach serves as a safe, effective, and minimally invasive alternative to surgical tumor removal. The company's flagship product, the ProSense ® system, is sold for approved indications worldwide, including in the United States, Europe, and Asia.
ProSense Cryoablation has become the first and only medical device to receive FDA approval in the United States for the treatment of breast cancer patients aged 70 and above with low tumor biology, tumors not exceeding 1.5 centimeters in size, and who are receiving adjuvant endocrine therapy, including those not suitable for surgery.
Investor Relations:
Meir Peleg, Chief Financial Officer+1-888-902-5716Forward-looking Statements
This press release contains “forward-looking statements” as defined by Section 27A of the Securities Act of 1933 (as amended) and Section 21E of the Securities Exchange Act of 1934 (as amended), and is intended to be protected under the “safe harbor” provisions established by these sections. Forward-looking statements are based on certain assumptions and describe the company’s future plans, strategies, and expectations, and can typically be identified by words such as “believes,” “expects,” “may,” “should,” “can,” “seeks,” “intends,” “plans,” “aims,” “estimates,” “projects,” and similar expressions. For example, the company’s discussion regarding the CNIPA patent grant, which is expected to expand the company’s global intellectual property portfolio and strengthen its protection of proprietary cryogenic technology in key international markets, as well as the company’s potential future intellectual property portfolio and its long-term growth strategies and objectives, are all considered forward-looking statements.
Important factors that could lead to significant differences between actual results, progress, and business decisions and those anticipated in these forward-looking statements include, but are not limited to: the company's planned revenue levels and capital expenditures; the company's available cash and its ability to obtain additional financing; the company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the company's ability to maintain relationships with suppliers, distributors, and other partners; the company's ability to maintain or protect the validity of its patents and other intellectual property; the company's ability to demonstrate and educate medical professionals about its products; political, economic, and military instability in the Middle East region, particularly in Israel; as well as factors listed in the "Risk Factors" section of the company's annual 20-F report for the year ended December 31, 2025, submitted to the U.S. Securities and Exchange Commission on March 17, 2026, and factors listed in other documents submitted or provided to the SEC, which can be viewed on the SEC website at www.sec.gov. Except as required by law, the company assumes no obligation to update these statements due to revisions or changes after the date of this press release.
